MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Exagen Accounts Payables 2011-2026 | XGN
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.15 M | 4.14 M | 3.13 M | 3.05 M | 2.49 M | 3.01 M | 1.48 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.15 M | 1.48 M | 3.06 M |
Quarterly Accounts Payables Exagen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.56 M | 2.51 M | 4.51 M | 4.14 M | 1.1 M | 2.33 M | 1.47 M | 3.13 M | 1.66 M | 1.31 M | 1.88 M | 3.05 M | 3.67 M | - | 4.21 M | 2.49 M | 1.51 M | 2.45 M | 2.17 M | 3.01 M | 3.01 M | 3.01 M | 3.01 M | 1.48 M | 1.48 M | 1.48 M | 1.48 M | 1.28 M | 1.28 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.51 M | 1.1 M | 2.42 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
446 M | $ 115.69 | 0.13 % | $ 35.2 B |  USA |
 |
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Illumina
ILMN
|
221 M | $ 128.66 | 0.61 % | $ 20.5 B | USA |
 |
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
1.88 M | $ 1.66 | -0.9 % | $ 2.21 M | USA |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | USA |
 |
Lantheus Holdings
LNTH
|
42.9 M | $ 84.24 | -0.11 % | $ 5.69 B | USA |
 |
Medpace Holdings
MEDP
|
28.1 M | $ 417.83 | 1.78 % | $ 12.1 B | USA |
 |
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
6.9 M | $ 24.81 | 1.43 % | $ 689 M | USA |
 |
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M |  Israel |
 |
CareDx, Inc
CDNA
|
9.99 M | $ 21.33 | 0.47 % | $ 1.14 B | USA |
 |
Senseonics Holdings
SENS
|
4.06 M | $ 7.17 | 1.7 % | $ 299 M | USA |
 |
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | USA |
 |
Soleno Therapeutics
SLNO
|
12.4 M | $ 52.75 | 0.06 % | $ 2.68 B | USA |
 |
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
176 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
18.4 M | $ 15.7 | -3.74 % | $ 475 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M |  China |
 |
Thermo Fisher Scientific
TMO
|
3.62 B | $ 467.48 | -0.45 % | $ 176 B | USA |
 |
Charles River Laboratories International
CRL
|
149 M | $ 171.6 | 1.08 % | $ 8.51 B | USA |
 |
Twist Bioscience Corporation
TWST
|
11.1 M | $ 61.18 | 0.39 % | $ 3.66 B | USA |
 |
Guardant Health
GH
|
54.4 M | $ 89.01 | 0.11 % | $ 11.2 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
983 K | $ 1.93 | -2.08 % | $ 8.54 M | USA |
 |
QIAGEN N.V.
QGEN
|
72.7 M | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
79.6 M | $ 9.58 | 0.42 % | $ 2.08 B | USA |
 |
Biomerica
BMRA
|
295 K | $ 2.15 | 0.7 % | $ 4.94 M | USA |
 |
National Research Corporation
NRC
|
1.17 M | $ 17.19 | -0.23 % | $ 385 M | USA |
 |
ICON Public Limited Company
ICLR
|
173 M | $ 101.81 | -0.35 % | $ 8.4 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
841 M | $ 263.75 | - | $ 21.9 B | USA |
 |
Celcuity
CELC
|
6.41 M | $ 124.21 | 2.62 % | $ 5.81 B | USA |
 |
OpGen
OPGN
|
245 K | - | -16.95 % | $ 1.54 M | USA |
 |
NeoGenomics
NEO
|
23.1 M | $ 8.48 | 2.29 % | $ 1.09 B | USA |
 |
Myriad Genetics
MYGN
|
30 M | $ 4.79 | 0.21 % | $ 444 M | USA |
 |
Natera
NTRA
|
31.1 M | $ 204.22 | 0.23 % | $ 20.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
307 M | $ 196.35 | 0.07 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
14 M | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
185 M | - | -0.91 % | $ 14.7 B | USA |